Company Statement - Shelf Life Reduction of Panvax® Junior

Company Statement - Shelf Life Reduction of Panvax® Junior

Melbourne, Australia — 25/08/2010

Ongoing monitoring by both CSL and the TGA of CSL’s Panvax® Junior vaccine has shown a decline in its potency and as a result a 12 month shelf life can no longer be supported. Panvax® Junior is the paediatric presentation of CSL’s 2009 H1N1 (pandemic) influenza vaccine, which is supplied in a single 0.25ml pre-filled syringe.

This situation is not unique. Regulators and manufacturers in other countries have identified similar trends in their single-dose monovalent H1N1 vaccines. The decline in potency is specific to the 2009 monovalent (single strain) H1N1 vaccine when presented in small volumes, such as Panvax® Junior. Panvax® (and other manufacturers’ H1N1 vaccines) in multi-dose vials are not affected, nor are trivalent seasonal influenza vaccines that contain the H1N1 strain.

Based on this information and following consultation with the TGA, a decision has been made to limit the shelf life of Panvax® Junior to 6 months and as a result, all remaining doses are now to be considered expired. CSL has written to immunisation providers to inform them of this decision and will be conducting a retrieval program for all remaining doses of Panvax® Junior.

Importantly, no unexpected safety or efficacy concerns have been identified with administration of Panvax® Junior. Panvax® Junior has been available for children aged 3 years and under since 9th December 2009.

Advice regarding influenza vaccinations for children is available at

Dr Darryl Maher
Senior Director, Medical & Research
CSL Biotherapies

Download the company statement:
PDF icon Company Statement - Shelf Life Reduction of Panvax® Junior

Media Contact:
Sharon McHale
Senior Director, Public Affairs
Phone: +61 3 9389 1506
Mobile: +61 409 978 314
© 2017 CSL Limited